HRP20110953T1 - Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji - Google Patents
Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji Download PDFInfo
- Publication number
- HRP20110953T1 HRP20110953T1 HR20110953T HRP20110953T HRP20110953T1 HR P20110953 T1 HRP20110953 T1 HR P20110953T1 HR 20110953 T HR20110953 T HR 20110953T HR P20110953 T HRP20110953 T HR P20110953T HR P20110953 T1 HRP20110953 T1 HR P20110953T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- phenyl
- disease
- optionally substituted
- pyridinyl
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 7
- -1 methanesulfonylmethyl Chemical group 0.000 claims 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical group C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000032140 Sleepiness Diseases 0.000 claims 2
- 206010041349 Somnolence Diseases 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000037321 sleepiness Effects 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
- KFIOZBMCNUODPK-UHFFFAOYSA-N n-phenyl-1-pyrrolidin-1-ylpyrrolidine-2-carboxamide Chemical class C1CCN(N2CCCC2)C1C(=O)NC1=CC=CC=C1 KFIOZBMCNUODPK-UHFFFAOYSA-N 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000000543 intermediate Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98060107P | 2007-10-17 | 2007-10-17 | |
| PCT/US2008/079760 WO2009052065A1 (en) | 2007-10-17 | 2008-10-14 | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110953T1 true HRP20110953T1 (hr) | 2012-01-31 |
Family
ID=40243633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110953T HRP20110953T1 (hr) | 2007-10-17 | 2011-12-19 | Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8618159B2 (zh) |
| EP (1) | EP2212282B1 (zh) |
| JP (1) | JP5255644B2 (zh) |
| KR (1) | KR20100092441A (zh) |
| CN (1) | CN101903339B (zh) |
| AT (1) | ATE525350T1 (zh) |
| AU (1) | AU2008312638B2 (zh) |
| BR (1) | BRPI0818626A2 (zh) |
| CA (1) | CA2702482C (zh) |
| CO (1) | CO6190616A2 (zh) |
| CY (1) | CY1112683T1 (zh) |
| DK (1) | DK2212282T3 (zh) |
| ES (1) | ES2374116T3 (zh) |
| HK (1) | HK1146054A1 (zh) |
| HR (1) | HRP20110953T1 (zh) |
| IL (1) | IL205003A0 (zh) |
| MA (1) | MA31855B1 (zh) |
| MX (1) | MX2010004094A (zh) |
| MY (1) | MY149650A (zh) |
| NZ (1) | NZ584688A (zh) |
| PL (1) | PL2212282T3 (zh) |
| PT (1) | PT2212282E (zh) |
| RU (1) | RU2477719C2 (zh) |
| SI (1) | SI2212282T1 (zh) |
| WO (1) | WO2009052065A1 (zh) |
| ZA (1) | ZA201001946B (zh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702834C (en) | 2007-10-17 | 2013-01-15 | Sanofi-Aventis | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof |
| CN101903340B (zh) * | 2007-10-17 | 2013-03-27 | 赛诺菲-安万特 | 取代的n-苯基联吡咯烷羧酰胺及其治疗用途 |
| KR20100082349A (ko) | 2007-10-17 | 2010-07-16 | 사노피-아벤티스 | 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 |
| AR074466A1 (es) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| AR074467A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| WO2011143145A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| EP2569304A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| JP5784110B2 (ja) * | 2010-05-11 | 2015-09-24 | サノフイ | 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用 |
| EP2569294B1 (en) | 2010-05-11 | 2015-03-11 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| EP2569297A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof |
| TW201206898A (en) * | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| JP5968307B2 (ja) * | 2010-05-11 | 2016-08-10 | サノフイ | 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用 |
| EP2714941A4 (en) * | 2011-05-24 | 2014-12-03 | Wistar Inst | COMPOSITIONS AND METHODS FOR MODULATING THE EFFECT OF THE EPSTEIN-BARR NUCLEAR ANTIGEN 1 |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| EP1556046A1 (en) * | 2002-10-23 | 2005-07-27 | Janssen Pharmaceutica N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DK1861360T3 (da) | 2005-03-17 | 2010-01-25 | Lilly Co Eli | Pyrrolidin-derivater som histamin-H3-receptorantagonister |
| EP1868991B1 (en) * | 2005-04-01 | 2014-07-30 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| CN101263112B (zh) * | 2005-07-01 | 2012-10-10 | 伊莱利利公司 | 组胺h3受体药物、其制备和治疗用途 |
| JP2009513590A (ja) * | 2005-10-27 | 2009-04-02 | ユセベ ファルマ ソシエテ アノニム | ラクタム又はラクタム誘導体部分を含む化合物、これらの製造方法、及びこれらの使用 |
| CN101903340B (zh) | 2007-10-17 | 2013-03-27 | 赛诺菲-安万特 | 取代的n-苯基联吡咯烷羧酰胺及其治疗用途 |
| CA2702834C (en) | 2007-10-17 | 2013-01-15 | Sanofi-Aventis | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof |
| KR20100082349A (ko) | 2007-10-17 | 2010-07-16 | 사노피-아벤티스 | 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 |
-
2008
- 2008-10-14 CA CA2702482A patent/CA2702482C/en not_active Expired - Fee Related
- 2008-10-14 KR KR1020107010545A patent/KR20100092441A/ko not_active Application Discontinuation
- 2008-10-14 MY MYPI2010001276A patent/MY149650A/en unknown
- 2008-10-14 NZ NZ584688A patent/NZ584688A/en not_active IP Right Cessation
- 2008-10-14 AU AU2008312638A patent/AU2008312638B2/en not_active Ceased
- 2008-10-14 BR BRPI0818626A patent/BRPI0818626A2/pt not_active IP Right Cessation
- 2008-10-14 WO PCT/US2008/079760 patent/WO2009052065A1/en active Application Filing
- 2008-10-14 PL PL08839473T patent/PL2212282T3/pl unknown
- 2008-10-14 EP EP08839473A patent/EP2212282B1/en active Active
- 2008-10-14 RU RU2010119560/04A patent/RU2477719C2/ru not_active IP Right Cessation
- 2008-10-14 JP JP2010530052A patent/JP5255644B2/ja not_active Expired - Fee Related
- 2008-10-14 PT PT08839473T patent/PT2212282E/pt unknown
- 2008-10-14 DK DK08839473.9T patent/DK2212282T3/da active
- 2008-10-14 SI SI200830482T patent/SI2212282T1/sl unknown
- 2008-10-14 AT AT08839473T patent/ATE525350T1/de active
- 2008-10-14 ES ES08839473T patent/ES2374116T3/es active Active
- 2008-10-14 CN CN2008801211996A patent/CN101903339B/zh not_active Expired - Fee Related
- 2008-10-14 MX MX2010004094A patent/MX2010004094A/es active IP Right Grant
-
2010
- 2010-03-15 US US12/724,035 patent/US8618159B2/en active Active
- 2010-03-18 ZA ZA201001946A patent/ZA201001946B/xx unknown
- 2010-04-11 IL IL205003A patent/IL205003A0/en unknown
- 2010-04-16 CO CO10044768A patent/CO6190616A2/es not_active Application Discontinuation
- 2010-05-17 MA MA32846A patent/MA31855B1/fr unknown
-
2011
- 2011-01-12 HK HK11100255.7A patent/HK1146054A1/xx not_active IP Right Cessation
- 2011-12-19 HR HR20110953T patent/HRP20110953T1/hr unknown
- 2011-12-21 CY CY20111101272T patent/CY1112683T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0818626A2 (pt) | 2015-09-29 |
| HK1146054A1 (en) | 2011-05-13 |
| CN101903339A (zh) | 2010-12-01 |
| US8618159B2 (en) | 2013-12-31 |
| CA2702482A1 (en) | 2009-04-23 |
| CY1112683T1 (el) | 2016-02-10 |
| ZA201001946B (en) | 2010-10-27 |
| SI2212282T1 (sl) | 2012-01-31 |
| MY149650A (en) | 2013-09-30 |
| RU2477719C2 (ru) | 2013-03-20 |
| AU2008312638B2 (en) | 2013-05-16 |
| JP2011500696A (ja) | 2011-01-06 |
| MX2010004094A (es) | 2010-04-30 |
| AU2008312638A1 (en) | 2009-04-23 |
| JP5255644B2 (ja) | 2013-08-07 |
| CO6190616A2 (es) | 2010-08-19 |
| RU2010119560A (ru) | 2011-11-27 |
| US20100173897A1 (en) | 2010-07-08 |
| KR20100092441A (ko) | 2010-08-20 |
| PL2212282T3 (pl) | 2012-02-29 |
| DK2212282T3 (da) | 2012-01-23 |
| EP2212282A1 (en) | 2010-08-04 |
| IL205003A0 (en) | 2010-11-30 |
| ES2374116T3 (es) | 2012-02-13 |
| CN101903339B (zh) | 2012-06-27 |
| MA31855B1 (fr) | 2010-11-01 |
| EP2212282B1 (en) | 2011-09-21 |
| NZ584688A (en) | 2011-12-22 |
| PT2212282E (pt) | 2012-01-09 |
| WO2009052065A1 (en) | 2009-04-23 |
| CA2702482C (en) | 2012-11-27 |
| ATE525350T1 (de) | 2011-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110953T1 (hr) | Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji | |
| JP2011500696A5 (zh) | ||
| HRP20110762T1 (hr) | Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji | |
| RU2010119530A (ru) | Замещенные n-фенилпирролидинилметилпирролидинамиды и их терапевтическое применение в качестве модуляторов рецептора н3 гистамина | |
| JP2011500693A5 (zh) | ||
| JP2010529081A5 (zh) | ||
| CA2702933A1 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| CA2455296A1 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors | |
| JP2007516941A5 (zh) | ||
| MX2012007409A (es) | Derivados de benzamida sustituidos. | |
| HRP20110226T1 (hr) | Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora | |
| JP2002535408A5 (zh) | ||
| RU2009143104A (ru) | Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2011500697A5 (zh) | ||
| JP2002523506A5 (zh) | ||
| JP2011500694A5 (zh) | ||
| JP2019535825A5 (zh) | ||
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| JP2002525280A5 (zh) | ||
| ATE399164T1 (de) | Antagonisten des opioidrezeptors | |
| JP2015536965A5 (zh) |